U021 Immunomodulatory Therapies and Cutaneous Lymphoma: Associations, Risks, and Clinical Implications
DESCRIPTION
This symposium explores the emerging association between immunomodulatory therapies and cutaneous lymphomas, with a focus on drugs such as TNF inhibitors, dupilumab, JAK inhibitors, and IL-17/IL-23 blockers. Through a review of current literature, case-based discussion, and expert insights, attendees will learn to distinguish causation from correlation, recognize clinical red flags, and apply best practices for diagnosis, monitoring, and referral. Designed for dermatologists and clinicians managing inflammatory skin diseases, this session aims to improve diagnostic accuracy and patient safety when using immune-targeting therapies.
LEARNING OBJECTIVES
Summarize current evidence linking specific immunomodulatory therapies to cutaneous lymphoma onset or progression
Distinguish correlation from causation in reported drug-cutaneous lymphoma associations
Develop a strategy for evaluating and managing patients with new or worsening skin disease while on immunomodulatory therapies
SCHEDULE
3:30 PM
Oral Immunosuppression and Cutaneous Lymphoma
Jo-Ann Latkowski, MD, FAAD
3:45 PM
The Era of Biologics: A Double-Edged Sword
Larisa J. Geskin, MD, FAAD
4:00 PM
Dupixent and Mycosis Fungoides
Shamir S. Geller, MD, IFAAD
4:15 PM
When Biologics Unmask or Accelerate CTCL: How to Recognize It Early and What to Do Next
Oleg Akilov, MD, PhD
DIRECTOR
Jo-Ann Latkowski, MD, FAAD
SPEAKERS
Oleg Akilov, MD, PhD
University of Pittsburgh
Shamir S. Geller, MD, IFAAD
Memorial Sloan Kettering Cancer Center
Larisa J. Geskin, MD, FAAD
Columbia University
HANDOUTS
DISCLOSURES
Oleg Akilov, MD, PhD
Actelion – Investigator(Grants/Research Funding); Adaptive Biotechnologies Corp – Investigator(Grants/Research Funding); Helsinn Healthcare – Advisory Board(Honoraria); Kyowa Hakko Kirin Pharma, Inc. – Advisory Board(Honoraria), Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding), Speaker(Honoraria); Mallinckrodt Pharmaceuticals – Investigator(Grants/Research Funding); Pfizer Inc. – Investigator(Grants/Research Funding); SkinJect Inc. – Consultant (1099 relationship)(Fees); Therakos, Inc. – Speaker(Honoraria); Trillium Therapeutics, Inc – Investigator(Grants/Research Funding);
Shamir S. Geller, MD, IFAAD
Sanofi – Consultant (1099 relationship)(Fees); snorkel – Consultant (1099 relationship)(Fees);
Larisa J. Geskin, MD, FAAD
Therakos, Inc. – Consultant(Grants/Research Funding);
Jo-Ann Latkowski, MD, FAAD
No financial relationships exist with ineligible companies.